SCHEMBL551750

SCHEMBL551750

COc1ccc(O)c(C(N)=O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
PLAU P00749 2/20 0.55
F2 P00734 1/20 0.55
F10 P00742 1/20 0.55
PLAT P00750 1/20 0.55
ALDH1A1 P00352 4/20 0.55
HPGD P15428 4/20 0.55
CYP3A4 P08684 2/20 0.55
MAPK1 P28482 2/20 0.55
KDM4E B2RXH2 6/20 0.54
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
MAPT P10636 4/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
HSD17B10 Q99714 3/20 0.54
LMNA P02545 2/20 0.54
TP53 P04637 2/20 0.54
ALOX12 P18054 2/20 0.54
TDP1 Q9NUW8 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenol SCHEMBL2468309 0.90 RAB9A (0.57) NPC1RAB9APLAUF2F10
SCHEMBL20798299 0.85 KDM4E (0.48) NPC1RAB9APLAUF2F10
SCHEMBL1447373 0.85 NPC1 (0.72) NPC1RAB9AALDH1A1HPGDCYP3A4
SCHEMBL2835948 0.84 PARP1 (0.55) NPC1RAB9AALDH1A1HPGDCYP3A4
SCHEMBL28093168 0.84 RAB9A (0.71) NPC1RAB9AALDH1A1HPGDCYP3A4
SCHEMBL23463926 0.83 PARP10 (0.61) NPC1RAB9APLAUF2F10
Potassium SCHEMBL31026152 0.83 NPC1 (0.70) NPC1RAB9AALDH1A1HPGDCYP3A4
SCHEMBL128781 0.82 CA1 (0.61) NPC1RAB9AALDH1A1HPGDCYP3A4
SCHEMBL6856233 0.82 NPC1 (0.58) NPC1RAB9APLAUF2F10
SCHEMBL29431885 0.82 CA1 (0.61) NPC1RAB9AALDH1A1HPGDCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116462603-A Synthesis method of o-hydroxy/o-aminobenzamide compound 常州工程职业技术学院 2023-07-21 CN disclosed
CN-103796648-B Method for treating inflammation and hypertension with gamma-aldone scavenger 范德比尔特大学 2019-10-25 CN disclosed
EP-2460799-B1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION FUJIFILM CORP (JP) 2018-05-02 EP disclosed
US-8957140-B2 Triazine derivative, ultraviolet absorber, and resin composition FUJIFILM CORPORATION (JP) 2015-02-17 US disclosed
US-8748520-B2 Polycarbonate resin composition containing triazine compound and molded article using the same FUJIFILM CORPORATION (JP) 2014-06-10 US disclosed
EP-2301995-B1 Polycarbonate resin composition containing triazine compound and molded article using the same FUJIFILM CORP (JP) 2013-11-06 EP disclosed
US-8404036-B2 Water-soluble near-infrared absorbing coloring matters and aqueous inks containing same NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-03-26 US disclosed
CN-102510861-A New triazine derivative, ultraviolet absorber, and resin composition FUJIFILM CORP 2012-06-20 CN disclosed
EP-2460799-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION FUJIFILM Corporation (JP) 2012-06-06 EP disclosed
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-05-31 US disclosed
US-4812565-A ANTIHISTAMINE INTERMEDIATES A. H. ROBINS COMPANY, INCORPORATED (US) 1989-03-14 US disclosed
US-4810795-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1989-03-07 US disclosed
US-4727152-A Intermediates useful in the preparation of fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof A. H. ROBINS COMPANY, INC. (US) 1988-02-23 US disclosed
US-4705853-A ANTIHISTAMINES A. H. ROBINS COMPANY, INC. (US) 1987-11-10 US disclosed
US-4642343-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1987-02-10 US disclosed
US-4604388-A Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof in a method of counteracting histamine A. H. ROBINS COMPANY, INCORPORATED (US) 1986-08-05 US disclosed
US-4592866-A Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof A. H. ROBINS COMPANY, INC. (US) 1986-06-03 US disclosed
EP-0107930-A2 Fused aromatic oxazepinones and sulphur analogues thereof and their preparation and use in counteracting histamine A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1984-05-09 EP disclosed
US-4082751-A ANTIALLERGENS BRISTOL-MYERS COMPANY (US) 1978-04-04 US disclosed
US-4031093-A ANTIALLERGENS BRISTOL-MYERS COMPANY (US) 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION C1R, RPSA, H1-2 NPC1 4182/4885RAB9A 2727/4885PLAU 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.